NVO is cutting 9,000 jobs, targeting DKK 8 billion in savings, and shifting focus to obesity and diabetes R&D to regain growth momentum.

The Danish drugmaker plans to cut 9,000 jobs or 11% of its workforce, which would save it 8 billion Danish krone ($1.25 billion) annually.

In recent weeks Novo Nordisk has secured several key label expansions for some of its products, which should contribute meaningfully to the company's results. The company's most famous weight ...

India’s anti-obesity pharmaceutical market is valued at ₹859 crore, having recorded a five-fold increase over five years with a 46% CAGR ...

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced today that David Moore, Executive Vice President, US Operations at Novo Nordisk A/S and President at ...

The Danish government has joined forces with Novo Holdings, the investment arm of Novo Nordisk’s controlling foundation, to anchor a €300 million, which is ...

Many drug trials are vetted by companies with ties to the drugmakers, raising concerns about conflicts of interest and patient safety.

The Issaquah-based wholesale retailer is collaborating with Novo Nordisk, the Danish pharmaceutical company that manufactures Wegovy and Ozempic.

COPENHAGEN: Novo Nordisk, the maker of blockbuster weight-loss drug Wegovy, said on Wednesday it will cut 9,000 jobs in a bid to reignite growth and fend off intense competition from U.S. rival Eli ...